ClinicalTrials.gg
RecruitingNCT07680790Updated Nov 10, 2026

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

A Phase 3 interventional study of Iza-bren and Osimertinib in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Recruiting at 205 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
850
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung — 14 open to participants now, 18 under way, 9 of them phase 3. izalontamab brengitecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
Largest of 18
850 · median 417
Started
2026
with 5 others
Phase 3
5 of 18
3 open now
Primary completion
2031-12
later than 16 of 17 live
Registered
15th of 18
by date
Lead sponsor
3 of 18
Bristol-Myers Squibb

Among the 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung, this one has the largest planned enrollment, is one of 6 that started in 2026, is one of 5 in phase 3, reaches primary completion later than 16 of the 17 other live ones, and was the 15th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About izalontamab brengitecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing izalontamab brengitecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • NSCLC
  • EGFR
  • First line
  • Izalontamab brengitecan
  • Osimertinib
  • ADC
  • IZABRIGHT-Lung02
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed non-squamous NSCLC, newly diagnosed locally advanced (Stage IIIB/IIIC), (Stage IVA/IVB), or recurrent disease not amenable to curative surgery or definitive radiotherapy and requiring systemic treatment
  • Participants must have documented EGFR-TKI-sensitizing mutation (exon 19 deletion or exon 21 L858R substitution)
  • Participants must have measurable extracranial disease per v1.1 as assessed by the investigator
  • Participants must have Performance Status 0-1

Exclusion criteria

Exclusion Criteria:

  • Participants must not have unstable, symptomatic, or uncontrolled , including brain, , and/or spinal cord compression
  • Participants must not have history of ILD/pneumonitis requiring treatment with (≥ Grade 2), or current or suspected ILD/pneumonitis
  • Participants must not have cardiac disease
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
850 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Iza-bren · Drug: Osimertinib

  • Active comparator
    Arm B

    Drug: Osimertinib · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin

Interventions

  • Specified dose on specified days

    Also known as: BMS-986507, BL-B01D1, Izalontamab brengitecan

  • Specified dose on days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to approximately 5 years

  2. PFS assessed by the investigator as per RECIST v1.1

    Time frame: Up to approximately 3 years

  3. Second Progression-Free Survival (PFS2) as assessed by the Investigator

    Time frame: Up to approximately 5 years

  4. Objective Response Rate (ORR) assessed by the BICR as per RECIST v1.1

    Time frame: Up to approximately 3 years

  5. Objective Response Rate (ORR) assessed by the investigator as per RECIST v1.1

    Time frame: Up to approximately 3 years

  6. Disease Control Rate (DCR) assessed by the BICR as per RECIST v1.1

    Time frame: Up to approximately 3 years

  7. Disease Control Rate (DCR) assessed by the investigator as per RECIST v1.1

    Time frame: Up to approximately 3 years

  8. Duration of Response (DOR) assessed by the BICR as per RECIST v1.1

    Time frame: Up to approximately 3 years

  9. Duration of Response (DOR) assessed by the investigator as per RECIST v1.1

    Time frame: Up to approximately 3 years

07

Study locations

10 of 205 sites recruiting
  • Local Institution - 0212
    Beverly Hills, California 90211, United States
    Not yet recruiting
    • Site 0212 · Contact
  • Local Institution - 0504
    Fullerton, California 92835, United States
    Not yet recruiting
    • Site 0504 · Contact
  • Local Institution - 0357
    La Jolla, California 92093, United States
    Not yet recruiting
    • Site 0357 · Contact
  • Rocky Mountain Cancer Centers
    Boulder, Colorado 80304, United States
    Recruiting
    • Hossein Maymani, Site 0520 · Contact000-000-0000
  • Local Institution - 0161
    Washington D.C., District of Columbia 20007, United States
    Not yet recruiting
    • Site 0161 · Contact
  • Local Institution - 0527
    Fort Myers, Florida 33901, United States
    Not yet recruiting
    • Site 0527 · Contact
  • Local Institution - 0366
    Orlando, Florida 32806, United States
    Not yet recruiting
    • Site 0366 · Contact
  • Cancer Care Centers of Brevard - Rockledge
    Palm Bay, Florida 32901, United States
    Recruiting
    • Venkat Pavan Kancharla, Site 0519 · Contact111-111-1111
  • Local Institution - 0526
    St. Petersburg, Florida 33701, United States
    Not yet recruiting
    • Site 0526 · Contact
  • Local Institution - 0524
    West Palm Beach, Florida 33401, United States
    Not yet recruiting
    • Site 0524 · Contact
  • Local Institution - 0185
    Chicago, Illinois 60611, United States
    Not yet recruiting
    • Site 0185 · Contact
  • Local Institution - 0207
    Ottawa, Illinois 61350, United States
    Not yet recruiting
    • Site 0207 · Contact
  • Local Institution - 0503
    Baltimore, Maryland 21202, United States
    Not yet recruiting
    • Site 0503 · Contact
  • Local Institution - 0537
    Baltimore, Maryland 21231, United States
    Not yet recruiting
    • Site 0537 · Contact
  • Local Institution - 0523
    Silver Spring, Maryland 20904, United States
    Not yet recruiting
    • Site 0523 · Contact
  • Local Institution - 0521
    Edina, Minnesota 55435-2150, United States
    Not yet recruiting
    • Site 0521 · Contact
  • Local Institution - 0364
    Saint Paul, Minnesota 55102, United States
    Not yet recruiting
    • Site 0364 · Contact
  • Washington University School Of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Christine Auberle, Site 0403 · Contact
  • Local Institution - 0402
    Omaha, Nebraska 68198, United States
    Not yet recruiting
    • Site 0402 · Contact
  • Local Institution - 0290
    Lebanon, New Hampshire 03756, United States
    Not yet recruiting
    • Site 0290 · Contact
  • Local Institution - 0183
    New Brunswick, New Jersey 08901, United States
    Not yet recruiting
    • Site 0183 · Contact
  • Local Institution - 0153
    New York, New York 10021, United States
    Not yet recruiting
    • Site 0153 · Contact
  • Local Institution - 0157
    The Bronx, New York 10461, United States
    Not yet recruiting
    • Site 0157 · Contact
  • Local Institution - 0385
    Charlotte, North Carolina 28204, United States
    Not yet recruiting
    • Site 0385 · Contact
  • Local Institution - 0438
    Sandusky, Ohio 44870, United States
    Not yet recruiting
    • Site 0438 · Contact
  • Local Institution - 0404
    Portland, Oregon 97213, United States
    Not yet recruiting
    • Site 0404 · Contact
  • Local Institution - 0487
    Easton, Pennsylvania 18045, United States
    Not yet recruiting
    • Site 0487 · Contact
  • Local Institution - 0200
    Sioux Falls, South Dakota 57104, United States
    Not yet recruiting
    • Site 0200 · Contact
  • Local Institution - 0199
    Memphis, Tennessee 38120, United States
    Not yet recruiting
    • Site 0199 · Contact
  • Texas Oncology
    Beaumont, Texas 77702, United States
    Recruiting
    • Ashok Malani, Site 0522 · Contact713-792-2740
  • Texas Oncology - DFW
    Dallas, Texas 75246, United States
    Recruiting
    • Kartik Konduri, Site 0525 · Contact214-370-1000
  • Texas Oncology - San Antonio
    San Antonio, Texas 78217, United States
    Recruiting
    • Krishna Alluri, Site 0529 · Contact210-656-7177
  • Local Institution - 0411
    Salt Lake City, Utah 84112, United States
    Not yet recruiting
    • Site 0411 · Contact
  • Local Institution - 0165
    Fairfax, Virginia 22031, United States
    Not yet recruiting
    • Site 0165 · Contact
  • Local Institution - 0530
    Fairfax, Virginia 22031, United States
    Not yet recruiting
    • Site 0530 · Contact
  • Shenandoah Oncology, P.C. (Shenandoah Oncology Associates, P.C.)
    Winchester, Virginia 22601, United States
    Recruiting
    • Michael McCusker Jr., Site 0528 · Contact
  • Local Institution - 0283
    Seattle, Washington 98104, United States
    Not yet recruiting
    • Site 0283 · Contact
  • Local Institution - 0502
    Morgantown, West Virginia 26505, United States
    Not yet recruiting
    • Site 0502 · Contact
  • Local Institution - 0077
    Mar del Plata, Buenos Aires B7602CBM, Argentina
    Not yet recruiting
    • Site 0077 · Contact
  • Local Institution - 0514
    Río Cuarto, Córdoba Province 5800, Argentina
    Not yet recruiting
    • Site 0514 · Contact
  • Local Institution - 0086
    Buenos Aires, C1122AAL, Argentina
    Not yet recruiting
    • Site 0086 · Contact
  • Local Institution - 0432
    Buenos Aires, C1199ABB, Argentina
    Not yet recruiting
    • Site 0432 · Contact
  • Local Institution - 0085
    Buenos Aires, C1280AEB, Argentina
    Not yet recruiting
    • Site 0085 · Contact
  • Local Institution - 0078
    Buenos Aires, C1426AGE, Argentina
    Not yet recruiting
    • Site 0078 · Contact
  • Local Institution - 0151
    Buenos Aires, C1426ANZ, Argentina
    Not yet recruiting
    • Site 0151 · Contact
  • Local Institution - 0424
    Camperdown, New South Wales 2050, Australia
    Not yet recruiting
    • Site 0424 · Contact
  • Local Institution - 0439
    Westmead, New South Wales 2145, Australia
    Not yet recruiting
    • Site 0439 · Contact
  • Local Institution - 0511
    Greenslopes, Queensland 4120, Australia
    Not yet recruiting
    • Site 0511 · Contact
  • Local Institution - 0492
    Adelaide, South Australia 5000, Australia
    Not yet recruiting
    • Site 0492 · Contact
  • Local Institution - 0447
    Clayton, Victoria 3168, Australia
    Not yet recruiting
    • Site 0447 · Contact
  • Local Institution - 0437
    Murdoch, Western Australia 6150, Australia
    Not yet recruiting
    • Site 0437 · Contact
  • Local Institution - 0253
    Vitória, Espírito Santo 29043-260, Brazil
    Not yet recruiting
    • Site 0253 · Contact
  • Local Institution - 0291
    Salvador, Estado de Bahia 40170-110, Brazil
    Not yet recruiting
    • Site 0291 · Contact
  • Local Institution - 0247
    Ijuí, Rio Grande do Sul 98700-000, Brazil
    Not yet recruiting
    • Site 0247 · Contact
  • Local Institution - 0252
    Florianópolis, Santa Catarina 88020, Brazil
    Not yet recruiting
    • Site 0252 · Contact
  • Local Institution - 0244
    Barretos, São Paulo 14784-400, Brazil
    Not yet recruiting
    • Site 0244 · Contact
  • Local Institution - 0249
    Campinas, São Paulo 13060-803, Brazil
    Not yet recruiting
    • Site 0249 · Contact
  • Local Institution - 0261
    Sorocaba, São Paulo 18030-005, Brazil
    Not yet recruiting
    • Site 0261 · Contact
  • Local Institution - 0255
    Rio de Janeiro, 20230-130, Brazil
    Not yet recruiting
    • Site 0255 · Contact
  • Local Institution - 0259
    São Paulo, 01246-000, Brazil
    Not yet recruiting
    • Site 0259 · Contact
  • Local Institution - 0059
    Edmonton, Alberta T6G1Z2, Canada
    Not yet recruiting
    • Site 0059 · Contact
  • Local Institution - 0056
    Vancouver, British Columbia V5Z4E6, Canada
    Not yet recruiting
    • Site 0056 · Contact
  • Jewish General Hospital
    Montreal, Quebec H3T1E2, Canada
    Recruiting
    • Jennifer Friedmann, Site 0058 · Contact514340822224915
  • Local Institution - 0057
    Montreal, Quebec H4A3J1, Canada
    Not yet recruiting
    • Site 0057 · Contact
  • Local Institution - 0040
    Regina, Saskatchewan S4T1A5, Canada
    Not yet recruiting
    • Site 0040 · Contact
  • Local Institution - 0517
    Beijing, Beijing Municipality 100142, China
    Not yet recruiting
    • Site 0517 · Contact
  • Local Institution - 0458
    Beijing, Beijing Municipality 101149, China
    Not yet recruiting
    • Site 0458 · Contact
  • Local Institution - 0535
    Chongqing, Chongqing Municipality 0, China
    Not yet recruiting
    • Site 0535 · Contact
  • Local Institution - 0470
    Chongqing, Chongqing Municipality 400030, China
    Not yet recruiting
    • Site 0470 · Contact
  • Local Institution - 0493
    Fuzhou, Fujian 350001, China
    Not yet recruiting
    • Site 0493 · Contact
  • Local Institution - 0457
    Fuzhou, Fujian 350014, China
    Not yet recruiting
    • Site 0457 · Contact
  • Local Institution - 0326
    Dongguan Shi, Guangdong 523059, China
    Not yet recruiting
    • Site 0326 · Contact
  • Local Institution - 0331
    Guangzhou, Guangdong 510080, China
    Not yet recruiting
    • Site 0331 · Contact
  • Local Institution - 0512
    Jiangmen, Guangdong 529000, China
    Not yet recruiting
    • Site 0512 · Contact
  • Local Institution - 0478
    Zhongshan, Guangdong 528403, China
    Not yet recruiting
    • Site 0478 · Contact
  • Local Institution - 0321
    Guilin, Guangxi 541199, China
    Not yet recruiting
    • Site 0321 · Contact
  • Local Institution - 0328
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Site 0328 · Contact
  • Local Institution - 0505
    Guiyang, Guizhou 550003, China
    Not yet recruiting
    • Site 0505 · Contact
  • Local Institution - 0330
    Haikou, Hainan 570000, China
    Not yet recruiting
    • Site 0330 · Contact
  • Local Institution - 0322
    Shijiazhuang, Hebei 050035, China
    Not yet recruiting
    • Site 0322 · Contact
  • Local Institution - 0343
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Site 0343 · Contact
  • Local Institution - 0298
    Anyang, Henan 455000, China
    Not yet recruiting
    • Site 0298 · Contact
  • Local Institution - 0341
    Weihui Shi, Henan 453100, China
    Not yet recruiting
    • Site 0341 · Contact
  • Local Institution - 0480
    Zhengzhou, Henan 450000, China
    Not yet recruiting
    • Site 0480 · Contact
  • Local Institution - 0423
    Zhengzhou, Henan 450008, China
    Not yet recruiting
    • Site 0423 · Contact
  • Local Institution - 0483
    Jingzhou, Hubei 0, China
    Not yet recruiting
    • Site 0483 · Contact
  • Local Institution - 0450
    Wuhan, Hubei 430022, China
    Not yet recruiting
    • Site 0450 · Contact
  • Local Institution - 0482
    Changsha, Hunan 410007, China
    Not yet recruiting
    • Site 0482 · Contact
  • Local Institution - 0467
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Site 0467 · Contact
  • Local Institution - 0536
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Site 0536 · Contact
  • Local Institution - 0306
    Changsha Shi, Hunan 410013, China
    Not yet recruiting
    • Site 0306 · Contact
  • Local Institution - 0531
    Lianyungang, Jiangsu 222061, China
    Not yet recruiting
    • Site 0531 · Contact
  • Local Institution - 0347
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Site 0347 · Contact
  • Local Institution - 0332
    Shenyang, Liaoning 110042, China
    Not yet recruiting
    • Site 0332 · Contact
  • Local Institution - 0464
    Xi'an, Shaanxi 710038, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0479
    Binzhou, Shandong 256603, China
    Not yet recruiting
    • Site 0479 · Contact
  • Local Institution - 0455
    Jinan, Shandong 250117, China
    Not yet recruiting
    • Site 0455 · Contact
  • Local Institution - 0413
    Linyi, Shandong 276027, China
    Not yet recruiting
    • Site 0413 · Contact
  • Local Institution - 0469
    Weifang Shi, Shandong 261000, China
    Not yet recruiting
    • Site 0469 · Contact
  • Local Institution - 0319
    Shanghai Shi, Shanghai Municipality 200120, China
    Not yet recruiting
    • Site 0319 · Contact

Showing the first 100 of 205 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2031, 63 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 63 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Sep 8, 2026
Primary completionEst.
Dec 30, 2031
CompletionEst.
Dec 30, 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
19 sites added, 22 sites removed. 192 sites changed recruiting status (189 now not yet recruiting, 3 now withdrawn)
Show 192 sites
  • Local Institution - 0212 · Beverly Hills, United Statesno status→Not yet recruiting
  • Local Institution - 0504 · Fullerton, United Statesno status→Not yet recruiting
  • Local Institution - 0357 · La Jolla, United Statesno status→Not yet recruiting
  • Local Institution - 0527 · Fort Myers, United Statesno status→Not yet recruiting
  • Local Institution - 0366 · Orlando, United Statesno status→Not yet recruiting
  • Local Institution - 0526 · St. Petersburg, United Statesno status→Not yet recruiting
  • Local Institution - 0524 · West Palm Beach, United Statesno status→Not yet recruiting
  • Local Institution - 0207 · Ottawa, United Statesno status→Not yet recruiting
  • Local Institution - 0503 · Baltimore, United Statesno status→Not yet recruiting
  • Local Institution - 0523 · Silver Spring, United Statesno status→Not yet recruiting
  • Local Institution - 0521 · Edina, United Statesno status→Not yet recruiting
  • Local Institution - 0364 · Saint Paul, United Statesno status→Not yet recruiting
  • Local Institution - 0403 · St Louis, United Statesno status→Not yet recruiting
  • Local Institution - 0402 · Omaha, United Statesno status→Not yet recruiting
  • Local Institution - 0290 · Lebanon, United Statesno status→Not yet recruiting
  • Local Institution - 0183 · New Brunswick, United Statesno status→Not yet recruiting
  • Local Institution - 0153 · New York, United Statesno status→Not yet recruiting
  • Local Institution - 0157 · The Bronx, United Statesno status→Not yet recruiting
  • Local Institution - 0385 · Charlotte, United Statesno status→Not yet recruiting
  • Local Institution - 0438 · Sandusky, United Statesno status→Not yet recruiting
  • Local Institution - 0404 · Portland, United Statesno status→Not yet recruiting
  • Local Institution - 0487 · Easton, United Statesno status→Not yet recruiting
  • Local Institution - 0200 · Sioux Falls, United Statesno status→Not yet recruiting
  • Local Institution - 0199 · Memphis, United Statesno status→Not yet recruiting
  • Local Institution - 0525 · Dallas, United Statesno status→Not yet recruiting
  • Local Institution - 0411 · Salt Lake City, United Statesno status→Not yet recruiting
  • Local Institution - 0165 · Fairfax, United Statesno status→Not yet recruiting
  • Local Institution - 0530 · Fairfax, United Statesno status→Not yet recruiting
  • Local Institution - 0283 · Seattle, United Statesno status→Not yet recruiting
  • Local Institution - 0502 · Morgantown, United Statesno status→Not yet recruiting
  • …and 162 more on the registry record
Show 19 added (11 United States, 3 China, 2 Taiwan, 1 Thailand, 1 Canada, 1 Italy)
  • Local Institution - 0520 · Boulder, United States
  • Cancer Care Centers of Brevard - Rockledge · Palm Bay, United States
  • Texas Oncology · Beaumont, United States
  • Texas Oncology - San Antonio · San Antonio, United States
  • Shenandoah Oncology, P.C. (Shenandoah Oncology Associates, P.C.) · Winchester, United States
  • Local Institution - 0535 · Chongqing, China
  • Local Institution - 0534 · Chengdu, China
  • China Medical University Hospital · Taichung, Taiwan
  • Local Institution - 0263 · Din Daeng, Thailand
  • Rocky Mountain Cancer Centers · Boulder, United States
  • Local Institution - 0185 · Chicago, United States
  • Local Institution - 0537 · Baltimore, United States
  • Jewish General Hospital · Montreal, Canada
  • Local Institution - 0536 · Changsha, China
  • Local Institution - 0093 · Bergamo, Italy
  • Local Institution - 0161 · Washington D.C., United States
  • Washington University School Of Medicine · St Louis, United States
  • Texas Oncology - DFW · Dallas, United States
  • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
Show 22 removed
  • Local Institution - 0520 · Pueblo, United States
  • Local Institution - 0519 · Palm Bay, United States
  • Local Institution - 0210 · Honolulu, United States
  • Local Institution - 0522 · Beaumont, United States
  • Local Institution - 0529 · San Antonio, United States
  • Local Institution - 0528 · Winchester, United States
  • Local Institution - 0494 · Abbotsford British Columbia, Canada
  • Local Institution - 0533 · Oakville, Canada
  • Local Institution - 0043 · Oshawa, Canada
  • Local Institution - 0012 · Toronto, Canada
  • Local Institution - 0045 · Toronto, Canada
  • Local Institution - 0407 · Laval, Canada
  • Local Institution - 0111 · Ulm, Germany
  • Local Institution - 0110 · Wangen, Germany
  • Local Institution - 0216 · Taipei, Taiwan
  • Local Institution - 0419 · Taipei, Taiwan
  • Local Institution - 0520 · Boulder, United States
  • Local Institution - 0058 · Montreal, Canada
  • Local Institution - 0093 · Bergamo, Italy
  • Local Institution - 0403 · St Louis, United States
  • Local Institution - 0525 · Dallas, United States
  • Local Institution - 0227 · Gaoxiongka, Taiwan
across 3 updates, Oct 8, 2026 – Nov 10, 2026
Start date
Sep 30, 2026→Sep 8, 2026 (actual)
Oct 8, 2026
Show all 3 updates
  1. Nov 10, 2026
    4 sites added, 3 sites removed
    Show 4 added (3 United States, 1 Taiwan)
    • Local Institution - 0161 · Washington D.C., United States
    • Washington University School Of Medicine · St Louis, United States
    • Texas Oncology - DFW · Dallas, United States
    • Kaohsiung Medical University Chung-Ho Memorial Hospital · Kaohsiung City, Taiwan
    Show 3 removed
    • Local Institution - 0403 · St Louis, United States
    • Local Institution - 0525 · Dallas, United States
    • Local Institution - 0227 · Gaoxiongka, Taiwan
    + 1 other change: verification date
  2. Oct 26, 2026
    6 sites added, 3 sites removed
    Show 6 added (3 United States, 1 Canada, 1 China, 1 Italy)
    • Rocky Mountain Cancer Centers · Boulder, United States
    • Local Institution - 0185 · Chicago, United States
    • Local Institution - 0537 · Baltimore, United States
    • Jewish General Hospital · Montreal, Canada
    • Local Institution - 0536 · Changsha, China
    • Local Institution - 0093 · Bergamo, Italy
    Show 3 removed
    • Local Institution - 0520 · Boulder, United States
    • Local Institution - 0058 · Montreal, Canada
    • Local Institution - 0093 · Bergamo, Italy
    + 1 other change: verification date
  3. Oct 8, 2026
    Not yet recruiting→Recruiting
    9 sites added, 16 sites removed. 192 sites changed recruiting status (189 now not yet recruiting, 3 now withdrawn)
    Show 192 sites
    • Local Institution - 0212 · Beverly Hills, United Statesno status→Not yet recruiting
    • Local Institution - 0504 · Fullerton, United Statesno status→Not yet recruiting
    • Local Institution - 0357 · La Jolla, United Statesno status→Not yet recruiting
    • Local Institution - 0527 · Fort Myers, United Statesno status→Not yet recruiting
    • Local Institution - 0366 · Orlando, United Statesno status→Not yet recruiting
    • Local Institution - 0526 · St. Petersburg, United Statesno status→Not yet recruiting
    • Local Institution - 0524 · West Palm Beach, United Statesno status→Not yet recruiting
    • Local Institution - 0207 · Ottawa, United Statesno status→Not yet recruiting
    • Local Institution - 0503 · Baltimore, United Statesno status→Not yet recruiting
    • Local Institution - 0523 · Silver Spring, United Statesno status→Not yet recruiting
    • Local Institution - 0521 · Edina, United Statesno status→Not yet recruiting
    • Local Institution - 0364 · Saint Paul, United Statesno status→Not yet recruiting
    • Local Institution - 0403 · St Louis, United Statesno status→Not yet recruiting
    • Local Institution - 0402 · Omaha, United Statesno status→Not yet recruiting
    • Local Institution - 0290 · Lebanon, United Statesno status→Not yet recruiting
    • Local Institution - 0183 · New Brunswick, United Statesno status→Not yet recruiting
    • Local Institution - 0153 · New York, United Statesno status→Not yet recruiting
    • Local Institution - 0157 · The Bronx, United Statesno status→Not yet recruiting
    • Local Institution - 0385 · Charlotte, United Statesno status→Not yet recruiting
    • Local Institution - 0438 · Sandusky, United Statesno status→Not yet recruiting
    • Local Institution - 0404 · Portland, United Statesno status→Not yet recruiting
    • Local Institution - 0487 · Easton, United Statesno status→Not yet recruiting
    • Local Institution - 0200 · Sioux Falls, United Statesno status→Not yet recruiting
    • Local Institution - 0199 · Memphis, United Statesno status→Not yet recruiting
    • Local Institution - 0525 · Dallas, United Statesno status→Not yet recruiting
    • Local Institution - 0411 · Salt Lake City, United Statesno status→Not yet recruiting
    • Local Institution - 0165 · Fairfax, United Statesno status→Not yet recruiting
    • Local Institution - 0530 · Fairfax, United Statesno status→Not yet recruiting
    • Local Institution - 0283 · Seattle, United Statesno status→Not yet recruiting
    • Local Institution - 0502 · Morgantown, United Statesno status→Not yet recruiting
    • …and 162 more on the registry record
    Show 9 added (5 United States, 2 China, 1 Taiwan, 1 Thailand)
    • Local Institution - 0520 · Boulder, United States
    • Cancer Care Centers of Brevard - Rockledge · Palm Bay, United States
    • Texas Oncology · Beaumont, United States
    • Texas Oncology - San Antonio · San Antonio, United States
    • Shenandoah Oncology, P.C. (Shenandoah Oncology Associates, P.C.) · Winchester, United States
    • Local Institution - 0535 · Chongqing, China
    • Local Institution - 0534 · Chengdu, China
    • China Medical University Hospital · Taichung, Taiwan
    • Local Institution - 0263 · Din Daeng, Thailand
    Show 16 removed
    • Local Institution - 0520 · Pueblo, United States
    • Local Institution - 0519 · Palm Bay, United States
    • Local Institution - 0210 · Honolulu, United States
    • Local Institution - 0522 · Beaumont, United States
    • Local Institution - 0529 · San Antonio, United States
    • Local Institution - 0528 · Winchester, United States
    • Local Institution - 0494 · Abbotsford British Columbia, Canada
    • Local Institution - 0533 · Oakville, Canada
    • Local Institution - 0043 · Oshawa, Canada
    • Local Institution - 0012 · Toronto, Canada
    • Local Institution - 0045 · Toronto, Canada
    • Local Institution - 0407 · Laval, Canada
    • Local Institution - 0111 · Ulm, Germany
    • Local Institution - 0110 · Wangen, Germany
    • Local Institution - 0216 · Taipei, Taiwan
    • Local Institution - 0419 · Taipei, Taiwan
    Start date Sep 30, 2026→Sep 8, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07680790
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Sep 8, 2026
Primary completion
Dec 30, 2031 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Izalontamab brengitecan

Start the discussion